Los Angeles - 
(NewMediaWire) - February 23, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. (“Pulse” or “the Company”) (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Pulse’s investigational device exemption (“IDE”) study of the CellFX System for the treatment of sebaceous hyperplasia lesions did not meet its primary endpoints. This failure increased the risk that the FDA would not approve the Company’s 510(k) submission seeking label expansion for CellFX. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Pulse, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm
View the original release on www.newmediawire.com
